CD274 and neoplasm: This system enables tumor microenvironment-selective drug release, simultaneously blocking extracellular PD-L1 while activating intracellular PD-L1 degradation mechanisms, thereby significantly enhancing antitumor immune responses (Zeng Z. et al., 2024).